CoLucid Pharmaceuticals to Present Corporate Overview at the BIO CEO & Investor Conference

CAMBRIDGE, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today announced that Thomas Mathers, Chief Executive Officer, will present a corporate overview at the BIO CEO & Investor Conference, being held in New York City February 8-9.

BIO CEO & Investor Conference -- CoLucid Presentation Details
Date:Tuesday, February 9
Time:2:30pm Eastern Time
Location:Waldorf Astoria, Conrad Room

About CoLucid Pharmaceuticals, Inc.
CoLucid was founded in 2005 and is developing oral lasmiditan for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.

Thomas Mathers Chief Executive Officer CoLucid Pharmaceuticals, Inc. (857) 285-6494 Hans Vitzthum Managing Director LifeSci Advisors, LLC. (212) 915-2568

Source:CoLucid Pharmaceuticals, Inc